Результаты поиска

Изучение клинической полезности нееврофильтрованных световых цепочек для управления множественным склерозом.

Множественный склероз (MS) — хроническое нервно-воспалительное и нейродегенеративное заболевание, которое воздействует почти на здоровье человека. 1 million взрослых в Соединенных Штатах. В связи с непредсказуемостью курса лечения заболеваний, разнообразием фенотипов и целым рядом имеющихся в настоящее время методов лечения, позволяющих видоизменить заболевания, требуется индивидуализированный подход к управлению MS. Существует неудовлетворенная потребность в выявлении, подтверждении и включении прогнозных, мониторинговых и прогнозных биомаркеров в обычную клиническую практику для MS. Усиливаю

The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis.

BACKGROUND: Immunoglobulin light chain (AL) amyloidosis is a rare, multi-systemic disorder characterized by two disease processes: an underlying plasma cell dyscrasia that provides the source of pathologic light chains, and the resulting organ dysfunction caused by deposition of amyloid light chain fibrils. There are no FDA approved treatments for AL amyloidosis; regimens developed for multiple myeloma are used off-label to treat the plasma cell disorder and no therapies are directed at organ deposition. Thus, an unmet medical need persists despite advances in disease management. A public-priv

Biomaterials from the sea: Future building blocks for biomedical applications.

Marine resources have tremendous potential for developing high-value biomaterials. The last decade has seen an increasing number of biomaterials that originate from marine organisms. This field is rapidly evolving. Marine biomaterials experience several periods of discovery and development ranging from coralline bone graft to polysaccharide-based biomaterials. The latter are represented by chitin and chitosan, marine-derived collagen, and composites of different organisms of marine origin. The diversity of marine natural products, their properties and applications are discussed thoroughly in t

Antibodies to watch in 2018.

The pace of antibody therapeutics development accelerated in 2017, and this faster pace is projected to continue through 2018. Notably, the annual number of antibody therapeutics granted a first approval in either the European Union (EU) or United States (US) reached double-digits (total of 10) for the first time in 2017. The 10 antibodies granted approvals are: brodalumab, dupilumab, sarilumab, guselkumab, benralizumab, ocrelizumab, inotuzumab ozogamicin, avelumab, duvalumab, and emicizumab. Brodalumab, however, had already been approved in Japan in 2016. As of December 1, 2017, nine antibody

Выявление потенциальных нервных сигналов, вызванных наркотиками, путем проведения непропорционального анализа базы данных FAERS.

Нейроргия, вызванная наркотиками, является широко распространенной и значительной негативной реакцией. В рамках этого исследования была проанализирована база данных системы представления информации о неблагоприятных явлениях (FAERS) в Соединенных Штатах Америки (продовольствие и наркотики)2004-2024) выявления соответствующих наркотиков и потенциальных механизмов. Мы провели анализ связей между наркотиками и нейронгией с использованием базы данных FAERS. Применялись методы непропорционального анализа, включая коэффициент вероятности представления отчетности (ROR), коэффициент пропорциональной о

Сфингосин-1-Фосфатные модуляторы для лечения ультразвукового колита: обзор наррации, сосредоточенный на безопасности.

Ульцеративный колит представляет собой хроническое иммуносодержащее воспалительное заболевание толстой кишки, которое вызывает значительную заболеваемость и повышает риск рака цвета. Был разработан ряд целевых методов лечения умеренно-сильного язвительного колита, что значительно улучшило его лечение. Озанимод и этирасимод, пероральные небольшие молекулярные препараты, являются последним дополнением. Они относятся к классу модуляторов сфингосин-1-фосфатного рецептора (S1PR) и являются первыми членами этого класса, получившими официальное утверждение на наличие язвительного колита. Они действую

Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs.

Reimbursement decisions on new oncology drugs are now often made while uncertainty remains about a drug's risk-benefit profile. One consequence of this is a delay in patient access to valuable new medicines. We share our perspectives on strategies to mitigate sources of uncertainty in the health technology assessment process. These include flexible approaches for evaluating the additional benefit, such as better use of surrogate endpoints and health-related quality of life data, and renewed research efforts to define the optimal target population and generate real-world evidence post-authorisa

Biological Nanocarriers in Cancer Therapy: Cutting Edge Innovations in Precision Drug Delivery.

Cancer is a highly detrimental and fatal illness that poses a significant threat to human well-being. The pattern of cancer treatment is continuously being optimized by the advancement of old treatment approaches and the invention of novel treatment modes. Nanotechnology-based approaches are emerging as powerful candidates in the development of these advanced methods for treating tumors. This article provides a concise overview of nanotechnology for cancer or cancer nanomedicine and its applications. In light of prevalent issues, such as inadequate precision in targeting initial chemotherapy d

Double Repositioning: Veterinary Antiparasitic to Human Anticancer.

Drug repositioning, the approach of discovering different uses for existing drugs, has gained enormous popularity in recent years in the anticancer drug discovery field due to the increasing demand for anticancer drugs. Additionally, the repurposing of veterinary antiparasitic drugs for the treatment of cancer is gaining traction, as supported by existing literature. A prominent example is the proposal to implement the use of veterinary antiparasitics such as benzimidazole carbamates and halogenated salicylanilides as novel anticancer drugs. These agents have revealed pronounced anti-tumor act

Integrating Artificial Intelligence, Circulating Tumor DNA, and Real-World Evidence to Optimize Hematologic Clinical Trials: Toward Adaptive and Learning Trial Designs.

The integration of emerging technologies and real-world data is transforming the landscape of hematologic clinical trials. Artificial intelligence (AI) offers remarkable capabilities for predictive modeling, patient stratification, and adaptive trial design, while circulating tumor DNA (ctDNA) provides a minimally invasive biomarker for disease monitoring, the early detection of relapse, and treatment response assessment. Concurrently, real-world evidence (RWE) complements traditional clinical trial data by capturing treatment effectiveness, safety, and patient outcomes in broader, heterogeneo

Результаты лечения мелфлюфена у пациентов с повторной/отправленной миеломой.

Объект < < Объект мельфалан флуфенамид > > (мельфлюфен) плюс дексаметазон полностью утвержден в Европе для пациентов с повторной/реферативной множественной миеломой (RRMM) ≥ 3 предыдущие линии терапии. Мы проанализировали эффективность и безопасность мелфлюфена в реальном мире. В этом ретроспективном анализе мы изучили базовые характеристики, эффективность и результаты безопасности с мелфлюфеном плюс дексаметазоном в группе 12 в Институте рака Даны-Фарбера, США. 5.5 предыдущие линии терапии. Three (больные)25%) страдал внематочной болезнью, three (В тыс.25%) цитогенетически высокор

Унификация одиссеи: искусственный интеллект для диагностирования и лечения редких заболеваний.

Подытожить текущие проблемы в диагностике и лечении редких заболеваний (РД), осветить последние достижения в области искусственного интеллекта (АИ) для РД и предложить модель будущего состояния лечения пациентов РД. Многодисциплинарный экспертный обзор с кратким изложением современных практических задач и мер по ограничению ставок в области РД-клиентов с учетом ключевых клинических и исследовательских соображений в отношении нормативных и экономических ограничений. 10,000 известные РД оказывают коллективное воздействие 1 В 10 Американцы, в целом 30 million Люди. Ежегодно на РД приходится свыше

Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016-2022).

Fluorine is characterized by high electronegativity and small atomic size, which provide this molecule with the unique property of augmenting the potency, selectivity, metabolic stability, and pharmacokinetics of drugs. Fluorine (F) substitution has been extensively explored in drug research as a means of improving biological activity and enhancing chemical or metabolic stability. Selective F substitution onto a therapeutic or diagnostic drug candidate can enhance several pharmacokinetic and physicochemical properties such as metabolic stability and membrane permeation. The increased binding a

The organization, weaknesses, and challenges of the control of thalidomide in Brazil: A review.

The drug thalidomide has resurged in the world market under restrictive conditions for marketing and use. In Brazil, there are still cases of pregnant women using thalidomide even after the implementation of laws that regulate the control of use (Law No. 10.651/2003 and Collegiate Board Resolution No. 11/2011). The objective of this study was to discuss the control of thalidomide use in Brazil, based on a scoping review of the scientific literature, documents, and data from the Ministry of Health. A total of 51 studies and documents related to the following subthemes were selected: (1) organiz

The global burden of disease attributable to high body mass index in 195 countries and territories, 1990-2017: An analysis of the Global Burden of Disease Study.

BackgroundObesity represents an urgent problem that needs to be properly addressed, especially among children. Public and global health policy- and decision-makers need timely, reliable quantitative information to develop effective interventions aimed at counteracting the burden generated by high body mass index (BMI). Few studies have assessed the high-BMI-related burden on a global scale.Methods and findingsFollowing the methodology framework and analytical strategies used in the Global Burden of Disease Study (GBD) 2017, the global deaths and disability-adjusted life years (DALYs) attributa

Совпадение в полном тексте источника
… High calorie food; food that is ultra-processed, highly energy-dense, and rich in fat, salt, and glycemic load; and carbonated beverages have become increasingly available and affordable, and such accessibility, together with food marketing and advertising and the widespread presence of transnational … Food systems transformations, ultra-processed food markets and the nutrition transition in Asia. Global Health. 2016;12(1):80 10.1186/s12992-016-0223-3 26. Pirgon O, Aslan N. The Role of Urbanization in Childhood Obesity. J Clin Res Pediatr Endocrinol. 2015;7(3):163–7. 10.4274/jcrpe.1984 27. …

Cardiovascular adverse events associated with targeted therapies for multiple myeloma: a pharmacovigilance study.

IntroductionMultiple myeloma (MM) is a leading cause of hematopoietic cancer-related mortality, accounting for 20% of deaths. MM-targeted therapies have demonstrated efficacy, and since 2015, the United States Food and Drug Administration (FDA) has approved five targeted drugs. However, their cardiovascular safety has not been comprehensively evaluated.ObjectiveThis study aimed to investigate the association between MM-targeted therapy and cardiovascular adverse events (AEs).MethodsDisproportionality analysis was conducted on reports from the FDA AE Reporting System database from 2014 to the s

Optimising patient centred drug development to realise impact.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Recent Advances in the Development and Utilization of Nanoparticles for the Management of Malignant Solid Tumors.

The purpose of nanotechnology-based drug delivery systems or novel drug delivery systems is to improve the effectiveness of therapy, and their promising properties have led to their increasing significance in the management of cancer. The researchers have primarily focused on designing novel nanocarriers, like nanoparticles (NPs), that can effectively deliver drugs to target cells and respond specifically to conditions particular to cancer. Whether passive or active targeting, these nanocarriers can deliver therapeutic cargoes to the tumor site to release the drug from the drug delivery system

Chemical Patterns of Proteasome Inhibitors: Lessons Learned from Two Decades of Drug Design.

Drug discovery now faces a new challenge, where the availability of experimental data is no longer the limiting step, and instead, making sense of the data has gained a new level of importance, propelled by the extensive incorporation of cheminformatics and bioinformatics methodologies into the drug discovery and development pipeline. These enable, for example, the inference of structure-activity relationships that can be useful in the discovery of new drug candidates. One of the therapeutic applications that could benefit from this type of data mining is proteasome inhibition, given that mult

Радиум - с момента открытия и до настоящего времени - обзор событий.

После его открытия радий первоначально пропагандировался в качестве терапевтического агента для широкого круга заболеваний, включая расстройства кожи, аллергию, проблемы зрения, боль в суставах и общее средство для укрепления здоровья. Однако последующие исследования продемонстрировали ее значительную радиологическую токсичность и вредное воздействие на здоровье человека. Несмотря на эти риски, более чем через сто лет после его открытия, некоторые радиевые изотопы по-прежнему имеют ограниченное применение в медицинских целях, особенно при лечении конкретных раковых заболеваний. После поглощени